Reuters logo
BRIEF-Sage Therapeutics advances SAGE-217
February 13, 2017 / 12:25 PM / 7 months ago

BRIEF-Sage Therapeutics advances SAGE-217

Feb 13 (Reuters) - Sage Therapeutics Inc -

* Sage Therapeutics advances SAGE-217 into placebo-controlled phase 2 clinical trial in major depressive disorder

* SAGE-217 was found to be generally well-tolerated with no serious adverse events or discontinuations reported

* Statistically significant mean change from baseline was observed by day 2 of study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below